Moxalactam Therapy for Neonatal Meningitis due to Gram-negative Enteric Bacilli: A Prospective Controlled Evaluation

Neonatal Meningitis Cooperative Study Group

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23% and 15% for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40% of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30%); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.

Original languageEnglish (US)
Pages (from-to)1427-1432
Number of pages6
JournalJAMA - Journal of the American Medical Association
Volume252
Issue number11
DOIs
StatePublished - Sep 21 1984

Fingerprint

Moxalactam
Meningitis
Bacillus
Ampicillin
Amikacin
Therapeutics
Population Characteristics
Hydrocephalus
Abscess
Survivors
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Moxalactam Therapy for Neonatal Meningitis due to Gram-negative Enteric Bacilli : A Prospective Controlled Evaluation. / Neonatal Meningitis Cooperative Study Group.

In: JAMA - Journal of the American Medical Association, Vol. 252, No. 11, 21.09.1984, p. 1427-1432.

Research output: Contribution to journalArticle

@article{d279220ead5c4a99959c7b9360bc802f,
title = "Moxalactam Therapy for Neonatal Meningitis due to Gram-negative Enteric Bacilli: A Prospective Controlled Evaluation",
abstract = "Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23{\%} and 15{\%} for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40{\%} of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30{\%}); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.",
author = "{Neonatal Meningitis Cooperative Study Group} and McCracken, {George H.} and Norma Threlkeld and Susan Mize and Baker, {Carol J.} and Kaplan, {Sheldon L.} and Idis Faingezicht and Feldman, {William E.} and Urs Schaad",
year = "1984",
month = "9",
day = "21",
doi = "10.1001/jama.1984.03350110027024",
language = "English (US)",
volume = "252",
pages = "1427--1432",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Moxalactam Therapy for Neonatal Meningitis due to Gram-negative Enteric Bacilli

T2 - A Prospective Controlled Evaluation

AU - Neonatal Meningitis Cooperative Study Group

AU - McCracken, George H.

AU - Threlkeld, Norma

AU - Mize, Susan

AU - Baker, Carol J.

AU - Kaplan, Sheldon L.

AU - Faingezicht, Idis

AU - Feldman, William E.

AU - Schaad, Urs

PY - 1984/9/21

Y1 - 1984/9/21

N2 - Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23% and 15% for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40% of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30%); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.

AB - Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23% and 15% for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40% of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30%); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.

UR - http://www.scopus.com/inward/record.url?scp=84944373547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944373547&partnerID=8YFLogxK

U2 - 10.1001/jama.1984.03350110027024

DO - 10.1001/jama.1984.03350110027024

M3 - Article

C2 - 6381775

AN - SCOPUS:84944373547

VL - 252

SP - 1427

EP - 1432

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 11

ER -